MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/0886022x.2023.2237124

Медицинская библиотека · Renal failure · 2023

Rituximab treatment for refractory nephrotic syndrome in adults: a multicenter retrospective study.

Ma Xiaoyan, Fang Lu, Sheng Lili, Zhou Xun, Bai Shoujun, Zang Xiujuan, Wang Yakun, Li Mengke, Lv Zexin, Zhong Qin, Yang Xinyu, Wang Yishu, Hu Yan, Yan Danying, Shi Yingfeng, Chen Hui, Li Jinqing, Tao Min, Zhuang Shougang, Wang Yi, Liu Na

Многоцентровое исследованиеСтатьяПеревод в очереди

Аннотация

BACKGROUND

The treatment of refractory nephrotic syndrome (RNS) is full of challenges and the role of rituximab (RTX) is not well-established, thus this study aims to demonstrate the role of RTX in RNS.

METHODS

This was a multicenter retrospective study of all adult patients receiving RTX for RNS. Patients enrolled were divided into two groups according to pathological pattern: 20 patients as a group of podocytopathy (including minimal change disease [MCD] and focal and segmental glomerulosclerosis [FSGS]), and 26 patients as membranous nephropathy (MN) group. The remission rate, relapse rate, adverse effects, and predictors of remission were analyzed.

RESULTS

A total of 75 patients received RTX for RNS and 48 were available for analysis after exclusion criteria. No significant difference in the remission rate at 6 or 12 months was observed between the MCD/FSGS and MN cases (p > 0.05). The median duration of the first complete remission (CR) was 1 month in the podocytopathy group and 12.5 months in the MN group. Three relapses were associated with infection as the ultimate outcome, and 6 out of 48 remained refractory representing a response rate of 87.5% in RNS. Clinical predictors of cumulative CR were estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 and mean arterial pressure (MAP) ≤103 mmHg at the beginning of therapy in patients with MN. No serious adverse effects were reported.

CONCLUSIONS

RTX appears to be effective in RNS across various clinical and pathological subtypes, exhibiting a low relapse rate and minimal significant side effects in the majority of patients.

Для цитирования: Ma Xiaoyan, Fang Lu, Sheng Lili, Zhou Xun, Bai Shoujun, Zang Xiujuan, Wang Yakun, Li Mengke, Lv Zexin, Zhong Qin, Yang Xinyu, Wang Yishu, Hu Yan, Yan Danying, Shi Yingfeng, Chen Hui, Li Jinqing, Tao Min, Zhuang Shougang, Wang Yi, Liu Na. Rituximab treatment for refractory nephrotic syndrome in adults: a multicenter retrospective study.. Renal failure. 2023. DOI: 10.1080/0886022x.2023.2237124.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.